LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
YETI Holdings
YETI
Dorian LPG
LPG
US Stock MarketDetailed Quotes
TAK Takeda Pharmaceutical
- 13.270
- +0.130+0.99%
Close Dec 27 16:00 ET
- 13.270
- 0.0000.00%
Post 20:01 ET
42.22BMarket Cap23.04P/E (TTM)
13.320High13.210Low1.19MVolume13.230Open13.140Pre Close15.84MTurnover0.04%Turnover Ratio46.08P/E (Static)3.18BShares14.74252wk High0.96P/B40.41BFloat Cap12.29352wk Low0.63Dividend TTM3.05BShs Float19.900Historical High4.76%Div YieldTTM0.84%Amplitude11.308Historical Low13.274Avg Price1Lot Size
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Company Profile
SymbolTAK
Company NameTakeda Pharmaceutical
Listing DateDec 24, 2018
Founded1781
CEOMr. Christophe Weber
MarketNYSE
Employees49281
Securities TypeDR
ADS Ratio2.0 : 1.0
Fiscal Year Ends03-31
Address4-1-1 Dosho-machi,Chuo-Ku
CityOsaka
ProvinceOsaka
CountryJapan
Zip Code540-8645
Phone81-6-6204-2111
Websitehttp://www.takeda.com
Company Executives
- Name
- Position
- Salary
- Akiko Amakawa
- Corporate Strategy Officer and Chief Executive Officer Chief of Staff
- --
- Christophe Weber
- Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.a., Inc.
- 1.70B
- Mwana Lugogo
- Chief Ethics and Compliance Officer
- --
- Milano Furuta
- Director and Chief Financial Officer
- --
- Takako Ohyabu
- Chief Global Corporate Affairs and Sustainability Officer
- --
- Gabriele Ricci
- Chief Data and Technology Officer
- --
- Lauren Duprey
- Chief Human Resources Officer
- --
- Elaine Shannon
- Global Quality Officer
- --
- Marcello Agosti
- Global Business Development Officer
- --
- Dr. Thomas Wozniewski, PhD
- Global Manufacturing and Supply Officer
- --
- Giles Platford
- President, Plasma-Derived Therapies Business Unit
- --
- Asuka Miyabashira
- President, Japan Pharma Business Unit
- --
- Ramona Sequeira
- President, Global Portfolio Division
- --
- Masami Iijima
- Chairman of the Board
- 43.00M
- Teresa Marie Bitetti
- President, Global Oncology Business Unit
- --
- Julie Kim
- President, U.S. Business Unit and U.S. Country Head
- --
- Andrew S. Plump, M.D.
- Director and President, Research and Development
- 12.00M
- Kimberly A. Reed
- Independent Director
- 41.00M
- Yoshiaki Fujimori
- Independent Director
- 40.00M
- Koji Hatsukawa
- Independent Director
- 43.00M
- Dr. John M. Maraganore,PhD
- Independent Director
- 39.00M
- Emiko Higashi
- Independent Director
- 49.00M
- Michel Orsinger
- Independent Director
- 46.00M
- Ian T. Clark
- Independent Director
- 44.00M
- Jean-Luc Butel
- Independent Director
- 38.00M
- Miki Tsusaka
- Independent Director
- 32.00M
- Dr. Steven Gillis, Pd.D
- Independent Director
- 44.00M
- Yoshihiro Nakagawa
- Global General Counsel
- --
